A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Key facts
- Where
- Budapest XII, MagyarországSee the site
- Phase
- 3. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you 18 years old or older?
Where in Magyarország
- Orszagos Onkologiai IntezetBudapest XII, MagyarországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- EU 2025-524160-38-00
- Record updated
- 2026. október 1.
- Original description
To assess OS in Cohort A and Cohort BRead full original descriptionShow less
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
To assess OS in Cohort A and Cohort B
Inclusion: Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active treatment in a belzutifan parent study.
Exclusion: Is currently on a dose interruption due to an Adverse Event (AE) in the parent study; once treatment has been resumed in the parent study, the participant is eligible to enroll; Has an on-going serious adverse event in the parent study, unless no longer hospitalized and considered clinically stable.